CXCL12 and myeloproliferative disorder: Additional evidence of MSC anti-tumorigenic function is the in vivo expansion of MPN-HSC and accelerated MPN progression observed in a murine model of the disease after Nestin+ MSC depletion and consequent reduction of MSC-derived CXCL12.